Xencor, Inc.

NASDAQ:XNCR

Biotechnology

Healthcare
$34.39 -1.03%

-$0.13 today

Market cap
$2.58B
Beta
0.93
P/E (TTM)
-5.5
EPS (TTM)
-$2.29
52W Low $6.92High $18.69

Volume 0.87M

Average 0.80M

XNCR Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Xencor, Inc.NASDAQ: XNCR

Gross Margin · Q2 FY2026 · quarter ended Jun 2026

Gross margin widens to 100.0%

Gross margin was 100.0% in Q2 FY2026, up 6.1 pp from a year earlier. On a trailing-twelve-month basis it was 43.3%, down 18.0 pp year over year. Over 3 fiscal years it widened by 112.9 pp.

Context

  • Gross margin widened in 2 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
100.0%+56.8 pp QoQ
Last fiscal yearDec 2025
91.6%+197.7 pp YoY
LTMJun 2026
43.3%-18.0 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+6.1 pp——
1 year+197.7 pp——
3 years+112.9 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
91.6%
Year-over-year change
+197.7pp

Gross Margin vs competitors

How XNCR compares with its peers on the latest reported figures

  • XNCR's LTM Jun 2026 gross margin of 43.3% is the 8th highest of the 11 companies compared; the peer median is 87.3%.
  • Its year-over-year change of -18.0 pp is the 8th highest of 9, against a peer median of +11.9 pp.
  • Over three fiscal years its change of +112.9 pp compares with a peer median of +0.9 pp.
XNCR Competitors Peer median
Gross Margin for XNCR and competitors
Company Period LTM level YoY 3-year change
IPHAInnate Pharma S.A.FY2025100.0% +0.0 pp+89.6 pp
NKTRNektar TherapeuticsLTM Jun 202699.4% +15.9 pp+23.5 pp
IMCRImmunocore Holdings plcLTM Mar 202698.8% -0.2 pp+1.6 pp
GMABGenmab A/SLTM Jun 202693.0% —-8.3 pp
CGENCompugen Ltd.LTM Mar 202688.1% +17.9 pp+0.3 pp
NRIXNurix Therapeutics, Inc.LTM Aug 202686.5% +249.4 pp+455.2 pp
MGNXMacroGenics, Inc.LTM Mar 202669.9% +7.9 pp-24.0 pp
XNCRXencor, Inc.LTM Jun 202643.3% -18.0 pp+112.9 pp
ADAGAdagene Inc.LTM Jun 2024-14.6% —+0.0 pp
CLDXCelldex Therapeutics, Inc.LTM Sep 2026-662.5% +5797.5 pp+3489.9 pp
IMMPImmutep LimitedFY2025-1117.6% -136.1 pp-6.4 pp
Peer median (excluding XNCR) 87.3%+11.9 pp+0.9 pp

Competitors are the stored peer set for XNCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue275.11M164.58M174.62M110.49M125.58M
Cost of Revenue192.51M199.56M0227.69M10.51M
Gross Profit82.6M(34.98M)174.62M(117.19M)115.06M
Gross Margin30.0%-21.3%100.0%-106.1%91.6%
Research & Development192.51M199.56M253.6M227.69M239.43M
Selling, General & Admin38.84M47.49M53.38M58.89M63.64M
Operating Expenses38.84M47.49M306.98M61.22M292.57M
Depreciation & Amortization7.49M8.8M11.5M12.11M10.51M
EBITDA90.14M(45.7M)(101.96M)(186.17M)(46.98M)
EBITDA Margin32.8%-27.8%-58.4%-168.5%-37.4%
Operating Income43.77M(82.47M)(132.36M)(178.41M)(177.5M)
Operating Margin15.9%-50.1%-75.8%-161.5%-141.4%
Interest Income862K4.82M18.63M31.93M27.52M
Interest Expense13K0036.64M31.93M
Other Income / Expenses38.86M27.97M12.73M(56.52M)87.87M
Income Before Tax82.63M(54.51M)(119.63M)(234.92M)(89.42M)
Pre-Tax Margin30.0%-33.1%-68.5%-212.6%-71.2%
Income Tax Expense0673K13.66M1.62M2.5M
Net Income82.63M(55.18M)(133.13M)(232.62M)(91.92M)
Net Margin30.0%-33.5%-76.2%-210.5%-73.2%
EPS (Basic)1.42(0.93)(2.08)(3.58)(1.24)
EPS (Diluted)1.37(0.93)(2.08)(3.58)(1.24)
Weighted Avg Shares58.38M59.65M60.5M65.04M74.24M
Weighted Avg Shares (Diluted)60.5M59.65M60.5M65.04M74.24M

Xencor, Inc.

NASDAQ:XNCR

Intrinsic Alpha fair value

Locked

Current Price

$34.39

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.